Opko Health is a healthcare company. Co.'s segments are diagnostics and pharmaceutical. Co.'s diagnostics segment provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare. Co.'s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity. The OPK stock yearly return is shown above.
The yearly return on the OPK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|